Kim JH, et al. - Researchers studied 3,001 Asian patients with chronic hepatitis B (CHB) receiving entecavir/tenofovir therapy from 2007 to 2017 to verify PAGE-B scores and Toronto hepatocellular carcinoma (HCC) risk index (THRI) in Asian patients with CHB. They also recommended modified PAGE-B scores to strengthen the predictive performance. Data revealed that in the derivation and validation datasets, the 5-year cumulative HCC incidence rates were 6.5% and 7.2% following entecavir/tenofovir onset. According to the findings, mPAGE-B scores including additional albumin levels demonstrated better predictive performance than the PAGE-B score, despite the fact that PAGE-B and THRI were appropriate in Asian CHB patients receiving entecavir/tenofovir therapy.